Wednesday, April 24, 2024
HomeViruses & VaccinesShortened hepatitis C treatment times can still cure patients

Shortened hepatitis C treatment times can still cure patients

A recent study presented at the annual meeting of the American Association for the Study of Liver Diseases in San Francisco, USA, demonstrated how significant cost savings could be made regarding hepatitis C treatment.

Hepatitis C is an infection resulting from a virus known as hepatitis C virus (HCV). The virusis spread through infected blood and can result in liver damage, liver failure, and liver cancer. Approximately 70 million individuals worldwide are infected with HCV.

To treat or cure hepatitis C, a class of medications called direct-acting anti-virals (DAA) are often administrated. Over 90% of patients are cured with the use of these medications with very little side effects, however, the cost of these medications are extremely high and thus limits the access to their use.

A recent study has provided preliminary data demonstrating that in 50% of patients, the standard 12-week treatment using these medications could be shortened to as little as six weeks without decreasing the effectiveness of the medications. The results were presented at the annual meeting of the American Association for the Study of Liver Diseases in San Francisco, USA, which took place between November 9-13, 2018.

A total of 22 patients have been enrolled in the study thus far, and 21 patients have remained free from the HCV infection following a shortened treatment regimen. The reason why one patient has not remained free from the HCV is because they have a difficult-to-treat HCV, known as genotype 3.

During this study, researchers have adopted a personalized medicine technique referred to as modelling-based response-guided therapy in order to decrease treatment times when possible. This study has demonstrated that using this response-guided therapy reducing treatment times is worthwhile, it does not compromise the efficacy of the treatment options but it does have the potential to produce cost savings of up to 20%.

To substantiate these results, a large multi-centre trial is now being carried out in Israel.

Written by Jade Marie Evans, MPharm, Medical Writer

Reference: Eurekalert . 2018. Hepatitis C treatment can be shortened in 50 percent of patients, study finds. [Online]. [21 November 2018]. Available from: https://www.eurekalert.org/pub_releases/2018-11/luhs-hct110618.php

Jade Evans MPharm
Jade Evans MPharm
Jade obtained her Master of Pharmacy degree from Cardiff University, UK in 2015 and then went on to work as a Pharmacist within the NHS, across both the hospital and community sectors. In 2017, she began her work for the medical news bulletin and moved to Perth, Australia. She is now working at Perth Children’s Hospital working in the Anaesthetic and Pain Management Research Group.
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest News and Articles

SUBSCRIBE TO OUR NEWSLETTERS

Stay Connected
10,288FansLike
820FollowersFollow
249FollowersFollow
2,787FollowersFollow

Article of the month

Augmented Reality to Augment Physical Therapy for Parkinson’s Disease

A hallmark of advancing Parkinson’s disease is a distinctive shuffling walk. Dual-task training is an effective but costly physical therapy that helps people with...

Joke Of The Day – April 24

Finally I realized why I get fat ... It is because of the shampoo!!! Today I read the label: "Strengthens and creates volume." From...

RECENT COMMENTS

ADVERTISE WITH US

error: Content is read-only and copy-protected.